Related Experiment Video

Updated: May 7, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice

J C Wilson1, M A O'Rorke, J A Cooper

  • 1Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen's University Belfast, UK.

Cancer Epidemiology
|September 18, 2013
PubMed
Abstract

Insights

This study found no link between non-steroidal anti-inflammatory drug (NSAID) or aspirin use and cervical cancer risk. Further research on NSAIDs and cancer prevention is warranted.

Area of Science:

  • Oncology
  • Pharmacology
  • Epidemiology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) exhibit anticarcinogenic properties by inhibiting cyclooxygenase 2 (COX-2).
  • Previous research on NSAIDs and cervical cancer risk yielded inconsistent findings, particularly differentiating between non-aspirin NSAIDs and aspirin.

Purpose of the Study:

  • To investigate the association between the use of NSAIDs, non-aspirin NSAIDs, and aspirin and the risk of developing cervical cancer.

Main Methods:

  • A large historical cohort study utilized the UK Clinical Practice Research Datalink.
  • 724 women with cervical cancer were compared to 3,479 matched controls.
  • Conditional logistic regression analysis adjusted for smoking, sexually transmitted infections, HRT, and contraceptive use.

Main Results:

  • No statistically significant association was found between ever use of NSAIDs, non-aspirin NSAIDs, or low-dose aspirin and cervical cancer risk.
  • Analysis of daily defined doses also revealed no association between NSAID or aspirin use and cervical cancer risk.

Conclusions:

  • This study provides no evidence to support an association between non-aspirin NSAID or aspirin use and cervical cancer risk.
  • The findings suggest that NSAIDs and aspirin do not significantly impact cervical cancer risk in the studied population.
Keywords:
Anti-inflammatory agentsAspirinNon-steroidalUterine cervical neoplasms

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...